PureTech Health (NASDAQ:PRTC) Trading Up 2% – Should You Buy?

Posted by Geri Gentry on May 21st, 2026

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC – Get Free Report)’s share price rose 2% on Wednesday . The company traded as high as $17.84 and last traded at $17.42. Approximately 7,177 shares traded hands during trading, a decline of 61% from the average daily volume of 18,326 shares. The stock had previously closed at $17.08.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Read Our Latest Analysis on PRTC

PureTech Health Stock Performance

The business has a 50-day moving average price of $16.85 and a two-hundred day moving average price of $17.20.

PureTech Health (NASDAQ:PRTC – Get Free Report) last posted its quarterly earnings data on Friday, April 10th. The company reported ($1.35) earnings per share for the quarter. The firm had revenue of $1.40 million during the quarter.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP boosted its holdings in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC – Free Report) by 50.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned approximately 0.31% of PureTech Health worth $1,388,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.